Recent studies of GM-CSF therapy in PAP have revealed variations in effectiveness according to disease severity, necessitating identification of potential biomarkers to determine which patients are likely to benefit from GM-CSF [38, 39]. Here, CSF2 is linked to pulmonary alveolar proteinosis.